Orbit & Endevica Bio collaborated to advance the development of cachexia therapies caused by cancer & other chronic conditions. By using Endevica’s technology platform, peptides can be altered to modify the activity of GPCRs behind the blood-brain barrier
The collaboration helps to advance Endevica’s development of GPCR-targeting therapies on receptor sets to its lead compound. The agreement combines Orbit’s peptide discovery capabilities & Endevica Bio’s expertise in drug development to facilitate the accelerated entry of complimentary therapeutics portfolios into the clinic
The agreement’s main goal is to find peptide hits from particular library populations using internal in silico & modeling tools directly applied to Orbit’s functional screening platform to find protein agonism
Ref: Businesswire | Image: Orbit
Related News:- Cardiovascular Systems, Inc. Reports the First Patient Enrollment of Diamondback 360 Peripheral Orbital Atherectomy System in Japan
